The Shift from nonalcoholic fatty liver disease to metabolic dysfunction–associated fatty liver disease

Wong, Rochelle; Fortune, Brett E.

doi:10.1002/cld.1250

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consensus groups began to meet to develop new nomenclature that would not rely on exclusionary confounder terms and use of stigmatizing language. There were many pros and cons to shifting from a binary, more widely familiar, potentially stigmatizing nomenclature to a more comprehensive, inclusive, less stigmatizing nomenclature to diagnose steatotic liver disease[ 2 ]. Ultimately in December 2023, the global Nonalcoholic Fatty Liver Disease Nomenclature Consensus Group published a new nomenclature that better defined criteria for steatotic liver disease, including MASLD, to facilitate diagnose and awareness of the disease[ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Sarcopenia and metabolic dysfunction associated steatotic liver disease: Time to address both

Wong,

Yuan

2024

World J Hepatol

Self Cite

View full text Add to dashboard Cite

Sarcopenia and metabolic dysfunction associated steatotic liver disease (MASLD) are closely intertwined. Sarcopenia, traditionally a disease of the older adult and chronic disease population, has been closely studied as one of the pathophysiologic conditions at play in the development of MASLD. They share similar risk factors of insulin resistance and physical inactivity. Given similar pathophysiology along the liver-muscle axis, sarcopenia has been studied as a risk factor for MASLD, and vice versa. Current research suggests a bidirectional relationship. Given the chronicity of MASLD as a chronic inflammatory liver disease, it can break down muscle mass and lead to sarcopenia, while sarcopenia promotes intramuscular lipid accumulation that releases cytokines that can aggravate inflammation in the liver. However, for the longest time, a lack of consensus definition for MASLD and sarcopenia made it difficult to study their relationship and outcomes. A recent nomenclature update to diagnosing MASLD has made it easier for researchers to identify cohorts for study. However, no gold standard technique to measure muscle mass or consensus sarcopenia definition has been identified yet. Future studies are needed to reach a consensus and reduce diagnostic variation. With similar pathophysiology and shared risk factors between the two diseases, future research may also identify potential therapeutic targets along the liver-muscle axis that would benefit both sarcopenia and MASLD in order to maximize their outcomes.

show abstract

Section: Introductionmentioning

confidence: 99%